FDA clearance lets you sell. Reimbursement decides whether anyone pays. The three questions every payer answer has to resolve, and what the new RAPID pathway changes.
An FDA clearance letter tells you that you are allowed to sell your device. It does not tell you that anyone is going to pay for it. That gap is where a medical device reimbursement strategy lives, and it is one of the most consistently underbuilt pieces of a commercial launch.
The disconnect shows up in the first serious sales conversation. A hospital administrator does not ask whether your technology is cleared. They ask which code it bills under, whether the payer will cover it for this patient population, and how much of the cost comes back. If the answer is vague, the deal stalls no matter how strong the clinical data is.
This post covers why reimbursement determines commercial outcomes, the three questions any reimbursement answer has to resolve, where most strategies break down, and what changed in 2026 that should reshape how early-stage medtech companies plan for coverage.
The lag between regulatory authorization and payment is measured in years, not months. A study published in JAMA Health Forum examined 64 devices and diagnostics authorized through the premarket approval and de novo pathways between 2016 and 2019 and found a median of 5.7 years from FDA authorization to at least nominal Medicare coverage.1
The distribution is worse than the median suggests. Only about 9% of those technologies hit a coverage milestone within two years, while roughly 72% waited at least three years. Smaller companies fared worst of all, with coverage probabilities ranging from about 5.6% after one year to 19% by year five.2 For a venture-backed company operating on an 18 month runway, a five year coverage timeline is not a policy inconvenience. It is an existential planning assumption.
This is the same structural problem we described in why FDA clearance is just the beginning. Clearance removes a legal barrier. Reimbursement removes the economic one, and the economic barrier is usually the taller of the two.
Reimbursement is often discussed as a single obstacle. In practice it is three separate problems, and a device can clear one while failing another. Any credible strategy has to answer all three, in this order.
A claim needs a code before it can be paid. Depending on the setting, that means CPT or HCPCS codes for the procedure or item, and ICD-10-PCS and MS-DRG assignment for inpatient care. New CPT codes are set by the AMA CPT Editorial Panel, and the path from application to an active code commonly runs 18 to 24 months.3 If your device fits an existing code, you have a shortcut. If it does not, coding becomes a multi-year workstream that has to start well before launch.
Coverage is the payer's policy decision about medical necessity. On the Medicare side that means national coverage determinations and the local coverage determinations issued by contractors. Commercial payers set their own policies and often, though not always, follow Medicare's lead. A code with no coverage policy behind it produces denials, not revenue.
Payment is the dollar amount, set through MS-DRGs for inpatient stays, ambulatory payment classifications for hospital outpatient care, the Physician Fee Schedule for professional services, and DMEPOS rates for durable equipment. For inpatient technologies, the New Technology Add-on Payment can supplement the DRG rate, currently reimbursing up to 65% of incremental cost, and 75% for certain qualifying products.4 Note that CMS has proposed repealing the alternative NTAP pathway for breakthrough devices, so this is an area to verify rather than assume.5
The failure patterns are remarkably consistent across companies and specialties.
Reimbursement work often begins once the regulatory team hands off, which is precisely too late. The evidence that persuades a payer is not always the evidence that satisfies a reviewer. Payers want comparative outcomes, economic impact, and data on the population they actually cover. If your pivotal trial did not capture those endpoints, you cannot add them retroactively.
Reimbursement frequently sits with regulatory or finance, disconnected from marketing and sales. The result is a technically correct coding memo that no one in the field can use. Reimbursement is a market access function, which means it belongs in the commercial plan alongside positioning, sales enablement, and KOL engagement.
Clinical superiority and budget impact are different arguments. Hospitals evaluate devices through value analysis committees that weigh cost per case, length of stay, readmissions, and staffing time. A company that can only describe clinical benefit is asking a financial committee to translate on its behalf, and that translation rarely goes in your favor.
Teams optimize for Medicare and assume commercial plans will follow. Sometimes they do. But if your addressable population skews younger, commercial and Medicaid coverage may matter more than a national coverage determination, and those policies require separate evidence and separate outreach.
The reimbursement landscape shifted this year. On April 23, 2026, CMS and the FDA announced the Regulatory Alignment for Predictable and Immediate Device coverage pathway, known as RAPID. The program aligns evidence expectations between the two agencies during the investigational stage rather than after market authorization. For participating devices, CMS intends to issue a proposed national coverage determination on the same day the device receives FDA marketing authorization, with coverage possible within 60 to 90 days.6
Eligibility is narrow. It applies to certain Class II and Class III breakthrough devices, and it requires an investigational device exemption study that includes Medicare beneficiaries and pre-agreed clinical outcomes. RAPID builds on the Transitional Coverage for Emerging Technologies pathway finalized in August 2024, which targets a national coverage determination within six months of authorization but accepts only about five candidates per year.7
The strategic implication matters more than the mechanics. Both pathways reward companies that made coverage decisions part of trial design. If you are structuring an IDE study right now, the reimbursement conversation is no longer something to schedule for after clearance. It is a design input, and the companies treating it that way will reach revenue years ahead of the ones that do not.
Four workstreams turn reimbursement from a compliance exercise into commercial infrastructure. They are sequential in emphasis but concurrent in practice.
Identify the care setting, the likely code, and the payers who matter for your population. Then work backward into the evidence those payers require, and get it into the study protocol while the protocol is still open. This is the single highest-leverage decision available to an early-stage device company.
Assemble the budget impact model, cost offset analysis, and health economic argument in parallel with clinical publication. Specialty societies are natural allies here, since they carry weight in both code applications and coverage advocacy, and their support takes time to earn.
Coding guides, payer policy trackers, prior authorization templates, appeal letters, and a value analysis committee packet. This is the layer that determines whether your reimbursement work reaches the people making purchasing decisions, and it is the layer most often skipped.
Covered lives by payer, denial and appeal rates, average days to payment, and prior authorization approval rates belong in your CRM next to pipeline. Reimbursement performance is marketing intelligence, because it tells you which accounts are winnable and which messaging is landing.
Reimbursement rarely shows up as a standalone project. It shows up as the reason a commercial launch does or does not convert. When Cicada rebuilt EpiWatch's web presence around its FDA-cleared status, the work included the CRM, nurture automation, and paid social program behind the prescription funnel, because a cleared device still needs a functioning path from awareness to a paid, fulfilled order. The same logic applied to our work with Conformal Medical following its $35M Series D, where KOL and clinical trial infrastructure were built together rather than sequentially. You can see more in our case studies.
A medical device reimbursement strategy is the plan for securing coding, coverage, and payment so that providers can bill for your device and be paid appropriately. It covers code selection or code application, Medicare and commercial payer coverage policy, payment rates by care setting, and the evidence and field materials needed to support all three.
Historically, a long time. Research published in JAMA Health Forum found a median of 5.7 years from FDA authorization to at least nominal Medicare coverage for novel devices, with only about 9% achieving a coverage milestone within two years. New CMS pathways including TCET and the 2026 RAPID program are designed to compress that timeline substantially for eligible breakthrough devices.
Before your pivotal trial protocol is finalized. Payers often require comparative and economic evidence that regulatory submissions do not, and that evidence cannot be added after the study closes. Under the RAPID pathway, coverage alignment now happens during the investigational stage, which makes early planning a competitive advantage rather than good hygiene.
Coverage is the payer's decision about whether a technology is medically necessary for a given patient and indication. Payment is the amount the payer will actually pay when the claim is submitted. A device can be covered at a payment rate too low to support adoption, which is why both need to be addressed in the same strategy.
Often, but not automatically. Commercial plans set independent medical policy and may require additional evidence or apply different criteria. If your target population skews younger than the Medicare population, commercial and Medicaid coverage may be more commercially significant than a national coverage determination.
A medical device reimbursement strategy is not paperwork that follows commercialization. It is one of the load-bearing walls holding it up. The companies that reach revenue quickly are the ones that decided early which code, which payers, and which evidence they were building toward, then equipped their commercial team to make that case in the room where purchasing decisions get made.
Map the pathway before the protocol locks. Build the economic story alongside the clinical one. Put it in the hands of the field. Then measure coverage the way you measure pipeline, because in medtech, they are the same number viewed from different sides.
Cicada is a MedTech launch partner that helps FDA-cleared companies bridge the gap between clearance and commercial success. Through market access messaging, KOL engagement programs, operational support, brand development, and precision-driven market expansion, Cicada aligns marketing, sales, and operations to build revenue-ready healthcare companies. Learn more at cicada.co or see how we do it.
1 MedTech Dive. "Median lag between FDA authorization and Medicare coverage hits 6 years: study." https://www.medtechdive.com/news/fda-authorization-medicare-coverage-devices-study/690610/
2 Stanford Mussallem Center for Biodesign. "Stanford Researchers Study the Timelines from FDA Authorization to Medicare Approval." https://med.stanford.edu/biodesign/our-impact/stories/stanford-researchers-study-the-timelines-from-fda-authorization-to-medicare-approval.html
3 Academic Entrepreneurship for Medical and Health Sciences. "Reimbursement Strategies and CPT Codes for Device Development." https://academicentrepreneurship.pubpub.org/pub/1fani3y6/release/4
4 CMS. "New Medical Services and New Technologies." https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/new-medical-services-and-new-technologies
5 Ropes & Gray. "CMS and FDA Propose Major Changes for Breakthrough Devices with Proposed Repeal of NTAP Alternative Pathway and New RAPID Coverage Pathway." https://www.ropesgray.com/en/insights/alerts/2026/05/cms-and-fda-propose-major-changes-for-breakthrough-devices-with-proposed-repeal-of-ntap-alternative
6 CMS. "CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices." https://www.cms.gov/newsroom/press-releases/cms-fda-announce-rapid-coverage-pathway-accelerate-patient-access-life-changing-medical-devices
7 CMS. "Final Notice: Transitional Coverage for Emerging Technologies (CMS-3421-FN)." https://www.cms.gov/newsroom/fact-sheets/final-notice-transitional-coverage-emerging-technologies-cms-3421-fn
We work with commercially-viable health technology companies that are ready to scale. If that sounds like you, let's talk.
Schedule a Call